Physician

Arsh Singh, M.D.

According to 2025 Medicare claims, Arsh Singh, M.D. (NPI: 1063712826) practices hematology/oncology in the Punta Gorda, FL market, with the plurality of this provider's patient population coming from Charlotte, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33980-2012.

Singh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,879 traditional Medicare patients, billed 395,492 HCPCS/CPT codes, and received $5,558,254 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,471 prescription claims across 374 beneficiaries totaling $3,369,853 in drug costs, led by Revlimid (Lenalidomide). DME data shows 42 claims. Open Payments data shows 91 records totaling $1,909. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $505,158 to $5,558,254. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $760,458 and ending at $3,369,853. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	448	64,767	$505,158
2016	473	94,894	$756,488
2017	409	135,426	$1,112,530
2018	585	5,614	$146,310
2019	634	11,948	$201,276
2020	1,165	265,596	$2,716,656
2021	1,526	326,803	$3,671,311
2022	1,405	276,959	$3,764,821
2023	1,731	364,334	$4,674,188
2024	1,879	395,492	$5,558,254

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	153	893	$760,458
2016	176	1,030	$1,202,803
2017	179	1,235	$1,888,480
2018	41	76	$219,737
2019	28	66	$92,249
2020	203	666	$865,722
2021	252	985	$885,792
2022	247	961	$1,411,162
2023	264	1,041	$2,166,620
2024	374	1,471	$3,369,853

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	11	$178
2021	N/R	24	$2,092
2022	N/R	25	$800
2023	N/R	85	$8,321
2024	N/R	42	$1,322

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	681	1,235	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	308	458	$65
96372	Injection of drug or substance under skin or into muscle	398	988	$11
36415	Insertion of needle into vein for collection of blood sample	1,297	2,947	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,209	2,883	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	49	1,330	$851,154
Pomalyst	Pomalidomide	29	812	$668,535
Cabometyx	Cabozantinib S-Malate	22	660	$557,392
Tagrisso	Osimertinib Mesylate	14	420	$234,549
Xtandi	Enzalutamide	14	420	$203,093

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	11	$777
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	18	$301
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	91	$1,909	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Arsh Singh, M.D.?

Tedicare shows public-source Medicare data for Arsh Singh, M.D. (NPI 1063712826), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Arsh Singh, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Arsh Singh, M.D.?

Arsh Singh, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Arsh Singh, M.D. have Open Payments data?

Arsh Singh, M.D. has 91 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.